IL17A and autoimmune disease: However, since 2015, the Food and Drug Administration (FDA) has authorized the use of IL‐17A‐targeting monoclonal antibodies for autoimmune diseases including psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.